Cannabinoid bioscience has come a long way. New York-based Axim Biotech…
Category: Therapeutic Areas
Read the original Exelexis-supported publication in Drug Metabolism & Disposition (DMD)….
Executive Summary The boundary between pharmacovigilance and regulatory affairs has never been thinner. As health authorities accelerate the digitization of safety reporting, tighten electronic…
Executive Summary Biosimilars have advanced from a promising idea to a proven pathway for expanding patient access to biologic therapies and easing pressure on…
Introduction Real-world evidence (RWE) is accelerating drug development by using routinely collected patient health data, known as real-world data (RWD), to deliver insights beyond…
NEWARK, Del.–(BUSINESS WIRE)–QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalysis and clinical trials announces the successful implementation of Oracle…
NEWARK, Del.—(BUSINESS WIRE)—QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalytics and clinical trials, is celebrating its 30-year anniversary in…
NEWARK, Del.—(BUSINESS WIRE)—QPS India, a subsidiary of QPS Holdings, LLC (QPS), a GLP/GCP-compliant global full-service Contract Research Organization, has achieved another significant milestone by…
Webinars
QPS and Bioanalysis Zone: Advancing Bioanalytical Method Development and Validation for Small Molecules in a Changing Regulatory Landscape
Click here to watch the webinar.
QPS and Bioanalysis Zone: Advancing Bioanalytical Method Development and Validation for Small Molecules in a Changing Regulatory Landscape
Click here to watch the webinar.
QPS Aids Development of Cannabinoid Chewing Gum, for MS Patients
August 11, 2015
Cannabinoid bioscience has come a long way. New York-based Axim Biotech is at the forefront, developing – among many other, related products – a multi-layered,
DMPK scientists from Exelixis and QPS publish on “Metabolism and Disposition of Cabozantinib in Healthy Male Volunteers and Pharmacologic Characterization of Its Major Metabolites” in DMD
July 27, 2015
Read the original Exelexis-supported publication in Drug Metabolism & Disposition (DMD). Cabozantinib (COMETRIQ®) inhibits the activity of tyrosine kinases including MET, VEGFRs and RET. These
Executive Summary The boundary between pharmacovigilance and regulatory affairs has never been thinner. As health authorities accelerate the digitization of safety reporting, tighten electronic…
Executive Summary Biosimilars have advanced from a promising idea to a proven pathway for expanding patient access to biologic therapies and easing pressure on…
Introduction Real-world evidence (RWE) is accelerating drug development by using routinely collected patient health data, known as real-world data (RWD), to deliver insights beyond…
NEWARK, Del.–(BUSINESS WIRE)–QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalysis and clinical trials announces the successful implementation of Oracle…
NEWARK, Del.—(BUSINESS WIRE)—QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalytics and clinical trials, is celebrating its 30-year anniversary in…
NEWARK, Del.—(BUSINESS WIRE)—QPS India, a subsidiary of QPS Holdings, LLC (QPS), a GLP/GCP-compliant global full-service Contract Research Organization, has achieved another significant milestone by…